Results 21 to 30 of about 138,627 (294)

Parenterally administered vancomycin in 29 dogs and 7 cats (2003‐2017)

Journal of Veterinary Internal Medicine, 2019
Background Vancomycin is commonly used to treat resistant bacterial infections in people. Reported adverse effects of vancomycin in people include acute kidney injury (AKI), neutropenia, and systemic allergic reaction.
Ian M. DeStefano, Annie S. Wayne, Elizabeth A. Rozanski, Jonathan M. Babyak   +3 more
doaj   +1 more source

Vancomycin-resistant enterococci: eradication using vancomycin? [PDF]

Critical Care, 2014
Patient-to-patient transmission enables vancomycin- resistant enterococci (VRE) outbreaks. Outbreak management is expensive and time consuming, and therefore the possibility of VRE eradication is desirable. Since vancomycin is scarcely absorbed in the gastrointestinal tract, treatment with vancomycin per os may result in very high gastrointestinal ...
J. van Prehn, AM Stemerding, Peter E. Spronk, H. K. F. van Saene   +3 more
openaire   +2 more sources

Iterative Chemical Engineering of Vancomycin Leads to Novel Vancomycin Analogs With a High in Vitro Therapeutic Index

Frontiers in Microbiology, 2018
Vancomycin is a glycopeptide antibiotic that inhibits transpeptidation during cell wall synthesis by binding to the D-Ala-D-Ala termini of lipid II. For long, it has been used as a last resort antibiotic.
Nigam M. Mishra, Izabela Stolarzewicz, Izabela Stolarzewicz, David Cannaerts, Joris Schuermans, Rob Lavigne, Yannick Looz, Bart Landuyt, Liliane Schoofs, Dominique Schols, Jan Paeshuyse, Peter Hickenbotham, Martha Clokie, Walter Luyten, Walter Luyten, Erik V. Van der Eycken, Erik V. Van der Eycken, Yves Briers, Yves Briers   +18 more
doaj   +1 more source

Vancomycin

Medical Clinics of North America, 1995
Vancomycin is a nontoxic glycopeptide antibiotic most often used to treat serious gram-positive infections, C. difficile diarrhea/colitis, and endocarditis and hemodialysis shunt prophylaxis. Vancomycin should not be added to drug regimens for gram-positive coverage, and the empiric use of vancomycin should be discouraged to avoid the emergence of VRE.
openaire   +2 more sources

Engineered Peptides‐Based Hybrid‐Nested Microneedle Effectively Treat Biofilm‐Infected Diabetic Wounds

Advanced Functional Materials, EarlyView.
A hybrid‐nested microneedle/cryogel scaffold (MQW‐CMg‐MOF) is designed for efficient biofilm removal and accelerated healing of diabetic wounds. The scaffold shows substantial biofilm removal in vitro and in a preclinical diabetic swine biofilm‐infected wound model compared to the control.
Syed Muntazir Andrabi, S. M. Shatil Shahriar, Yiran Tian, Farzad Hayati, Yajuan Su, Feng Zhang, Navatha Shree Sharma, Guangshun Wang, Shannon L. Wong, Zheng Yan, Guoliang Huang, Jingwei Xie   +11 more
wiley   +1 more source

Nanocarrier‐Based Targeting of Pattern Recognition Receptors as an Innovative Strategy for Enhancing Sepsis Therapy

Advanced Healthcare Materials, EarlyView.
This review highlights recent progress in nanocarriers targeting pattern recognition receptors (PRRs), including Toll‐like and NOD‐like receptors, for enhancing the treatment of bacterial sepsis and related complications. These nanomedicines deliver antibiotics and anti‐inflammatory agents while modulating immune responses.
Eman A. Ismail, Vincent O. Nyandoro, Calvin A. Omolo, Thirumala Govender   +3 more
wiley   +1 more source

Metal–Organic Framework‐Based Antimicrobial Touch Surfaces to Prevent Cross‐Contamination

Advanced Materials, EarlyView.
A MOF‐based antimicrobial door handle cover is developed. It completely inhibits the cross‐contamination of Gram‐positive bacterial species (Staphylococcus aureus, and Enterococcus faecalis), Gram‐negative bacterial species (Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii), and fungi (Candida albicans). Abstract Infection diseases
Javier Fonseca, Mary Cano‐Sarabia, Pilar Cortés, Jordi Saldo, David Montpeyó, Julia Lorenzo, Montserrat Llagostera, Inhar Imaz, Daniel Maspoch   +8 more
wiley   +1 more source

Vancomycin-resistant Staphylococcus aureus (VRSA) can overcome the cost of antibiotic resistance and may threaten vancomycin's clinical durability.

PLoS Pathogens
Vancomycin has proven remarkably durable to resistance evolution by Staphylococcus aureus despite widespread treatment with vancomycin in the clinic. Only 16 cases of vancomycin-resistant S. aureus (VRSA) have been documented in the United States.
Samuel E Blechman, Erik S Wright
doaj   +1 more source

Appropriate vancomycin use in a Malaysian tertiary hospital based on current HICPAC recommendations

Journal of Infection in Developing Countries, 2014
Introduction: Antibiotic resistance is a rapidly emerging problem. A major concern is methicillin-resistant Staphylococcus aureus (MRSA), especially in developing countries where cost-effectiveness is imperative.
Farida Islahudin, Hui-Yeah Ong
doaj   +1 more source

State‐of‐the‐Art, Insights, and Perspectives for MOFs‐Nanocomposites and MOF‐Derived (Nano)Materials

Advanced Materials, EarlyView.
Different approaches to MOF‐NP composite formation, such as ship‐in‐a‐bottle, bottle‐around‐the‐ship and in situ one‐step synthesis, are used. Owing to synergistic effects, the advantageous features of the components of the composites are beneficially combined, and their individual drawbacks are mitigated.
Stefanos Mourdikoudis, Subhajit Dutta, Saqib Kamal, Sergio Gómez‐Graña, Isabel Pastoriza‐Santos, Stefan Wuttke, Lakshminarayana Polavarapu   +6 more
wiley   +1 more source